arrow
Z

Zenggang Pan

university of colorado anschutz medical campus
H指数:21
被引数:1,529

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

TP53突变髓系肿瘤中≥5%原始细胞染色体5异常的表征:一项国际TP53研究者网络(iTiN)研究

Cancer
IF5.1
2026-01-010
OAAI
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis

活体巨噬细胞和DLBCL细胞中促炎性GSDMD的激活标志着配体相互作用和更好的预后

2025-12-080
OAAI
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial

奥马曲拉和氮杂胞苷用于初治的伴有过多 blasts 的骨髓增生异常综合征患者的 I/II 期临床试验

2025-10-100
OAAI
Genomic profiling of pediatric mycosis fungoides, lymphomatoid papulosis z, and primary cutaneous anaplastic large cell lymphoma identifies recurrent tyrosine kinase gene fusions

儿童真菌样霉菌病、淋巴瘤样丘疹病Z和原发性皮肤间变性大细胞淋巴瘤的基因组分析鉴定出复发性酪氨酸激酶基因融合。

2025-10-080
PRE
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

预后基因表达和微RNA表达谱特征以及原发性睾丸弥漫性大B细胞淋巴瘤的遗传改变

2025-07-170
PREAI
Erythroblastic Sarcoma in Adult and Pediatric Populations: different pathways to the same destination
2025-03-010
PRE
Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

奥马扎克汀和阿扎胞苷用于新诊断的伴有过多原始细胞的骨髓增生异常综合征患者

BLOOD
IF23.1
2024-11-050
PRE
Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

深度学习基于骨髓涂片图像数据预测新诊断急性髓系白血病患者的维奈克拉和阿扎胞苷治疗反应

BLOOD
IF23.1
2024-11-050
PRE
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
2023-04-0310
OAAI
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
2022-10-0117
OAAI